Brokerages Set Cardlytics, Inc. (NASDAQ:CDLX) PT at $6.42

Cardlytics, Inc. (NASDAQ:CDLXGet Free Report) has earned an average rating of “Hold” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.42.

A number of brokerages recently commented on CDLX. Lake Street Capital dropped their target price on Cardlytics from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Thursday, March 13th. Evercore ISI decreased their price objective on shares of Cardlytics from $4.00 to $3.00 and set an “in-line” rating for the company in a research note on Thursday, March 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research note on Thursday, March 13th.

View Our Latest Report on CDLX

Insider Buying and Selling at Cardlytics

In related news, CEO Amit Gupta sold 46,857 shares of Cardlytics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $159,313.80. Following the completion of the transaction, the chief executive officer now directly owns 418,637 shares in the company, valued at $1,423,365.80. The trade was a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Alexis Desieno sold 24,778 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total value of $84,245.20. Following the completion of the sale, the chief financial officer now directly owns 140,948 shares in the company, valued at approximately $479,223.20. The trade was a 14.95 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,172 shares of company stock valued at $313,759. 4.40% of the stock is owned by company insiders.

Institutional Trading of Cardlytics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDLX. Mirabella Financial Services LLP acquired a new stake in shares of Cardlytics during the 4th quarter worth about $4,285,000. D. E. Shaw & Co. Inc. boosted its position in Cardlytics by 97.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company’s stock worth $4,198,000 after acquiring an additional 558,235 shares during the last quarter. Geode Capital Management LLC grew its stake in Cardlytics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company’s stock worth $3,936,000 after acquiring an additional 7,561 shares during the period. RBF Capital LLC raised its holdings in Cardlytics by 64.7% in the 4th quarter. RBF Capital LLC now owns 803,763 shares of the company’s stock valued at $2,982,000 after acquiring an additional 315,635 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Cardlytics by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 402,552 shares of the company’s stock valued at $1,493,000 after acquiring an additional 12,209 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Price Performance

NASDAQ CDLX opened at $1.50 on Tuesday. The firm’s fifty day simple moving average is $2.22 and its two-hundred day simple moving average is $3.17. The firm has a market capitalization of $78.13 million, a P/E ratio of -0.25 and a beta of 1.39. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics has a 12-month low of $1.22 and a 12-month high of $15.89.

Cardlytics Company Profile

(Get Free Report

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Read More

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.